Leadership & Pay ·
Greg Tourangeau departed as Vice President of Finance and principal accounting officer on August 7, 2026, following a…
FULCFulcrum Therapeutics, Inc.
Greg Tourangeau departed as Vice President of Finance and principal accounting officer on August 7, 2026, following a mutual agreement previously disclosed in June. Alan Musso, the company's chief financial officer and principal financial officer, was appointed as principal accounting officer effective August 7, 2026, with no additional compensation. Fulcrum Therapeutics operates in the biotechnology industry, focusing on developing treatments for rare genetic diseases.